pyrazines has been researched along with 2019 Novel Coronavirus Disease in 197 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 197 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, G; Alhashem, J; Alkhalifah, S; ALKhawajah, S; ALmarzooq, M; Almoosa, Z; Alshab, D; ALzain, M; Anshasi, N; Mansour, A; Mustafa, M; Mutair, AA; Qara, S; Saad, M | 1 |
| Kulkarni, A; Nasa, P; Shrivastava, PK; Singh, A; Vijayan, L | 1 |
| Alkan, M; Demirkol, MA; Dinc, V; Esatoglu, SN; Kamat, S; Kostek, ME; Sargin Altunok, E; Satici, C; Toprak, ID; Yazla, S | 1 |
| Abbasov, H; Abishov, E; Aksu, T; Akyay, A; Albayrak, C; Andıç, N; Ar, MC; Ataş, Ü; Aydın Kaynar, L; Balık Aydın, B; Baş, V; Baydar, M; Beköz, HS; Beksaç, M; Bolaman, AZ; Can, F; Çelik, S; Çeneli, Ö; Cengiz Seval, G; Çiftçiler, R; Civriz Bozdağ, S; Demir, AM; Demirci, U; Demircioğlu, S; Diz Küçükkaya, R; Doğan, A; Eroğlu Küçükdiler, H; Erol, V; Göksoy, HS; Güler, N; Gündüz, E; Gürman, G; Gürsoy, V; Güven, ZT; Hindilerden, F; İlhan, O; İnce, İ; Kaynar, L; Keklik, M; Kurt Yüksel, M; Maral, S; Mutlu, YG; Özcan, M; Özkalemkaş, F; Özkocaman, V; Özkurt, ZN; Özsan, GH; Sadri, S; Selim, C; Sevindik, ÖG; Terzi, H; Topçuoğlu, P; Toprak, SK; Ünal, Ş; Üsküdar Teke, H; Yağcı, M; Yavaşoğlu, İ; Yavuz, B; Yavuz, Y; Yegin, ZA; Yılmaz, U; Yönal Hindilerden, İ; Yücel, OK | 1 |
| Abdelnabi, R; Augustijns, P; Breuer, J; Chatterjee, AK; Coelmont, L; Dallmeier, K; De Jonghe, S; Do, TND; Foo, CS; Heylen, E; Jochmans, D; Kaptein, SJF; Langendries, L; Leyssen, P; Mols, R; Neyts, J; Pang, J; Vangeel, L; Vergote, V; Weynand, B; Williams, R; Zhang, X | 1 |
| Assis, LC; da Cunha, EFF; de Almeida La Porta, F; de Castro Ramalho, T; de Castro, AA; de Jesus, JPA; Kuca, K; Nepovimova, E | 1 |
| Hirota, T; Itoh, K; Iwasaki, H; Sakamaki, I | 1 |
| Kahraman, ME; Özbuğday, Y; Yüksel, F | 1 |
| Tsanni, A | 1 |
| Mungmunpuntipantip, R; Wiwanitkit, V | 2 |
| Atli, Z; Aydin, T; Balkan, II; Fresko, I; Hamuryudan, V; Hatemi, G; Melikoglu, M; Ozcifci, G; Ozguler, Y; Oztas, M; Seyahi, E; Tabak, F; Ugurlu, S | 1 |
| Daye, M; Oltulu, P | 1 |
| Nayak, CA; Raiturcar, TP | 1 |
| Allen, M; Chorlton, J; Hollowood, Z; Lockhart, D; Martin, J; McCafferty, K | 1 |
| Abolnezhadian, F; Alavi, SM; Ghafourian, M; Khodadadi, A; Mahmoudian-Sani, MR; Nashibi, R; Sharhani, A; Shohan, M | 1 |
| Tırmıkçıoğlu, Z | 1 |
| Doi, Y; Iwasaki, H; Koseki, T; Mizuno, T; Nakajima, K; Takahashi, K; Yamada, S | 1 |
| Chinnairusan, M; Dhanasekaran, S; Kagithakara Vajravelu, L | 1 |
| Hasan, SS; Kow, CS; Ramachandram, DS | 1 |
| Abdallah, IA; Bedair, A; Hammad, SF; Mansour, FR | 1 |
| Ikejima, K; Imai, R; Kurihara, Y; Matsusako, M; Ohde, S; Yamada, D | 1 |
| Arikan, H; Asicioglu, E; Barutcu Atas, D; Kaya, B; Tuglular, S; Tukenmez Tigen, E; Velioglu, A | 1 |
| Ansari, A; Barkate, H; Bhagat, S; Dhar, R; Lakhe, M; Panchal, S; Patil, S; Talwar, D; Tiwaskar, M | 1 |
| Chaturvedi, N; Chauhan, P; Karthic, A; Kesarwani, V; Kushwaha, SK; Singh, RK; Yadav, BS; Yadav, PK | 1 |
| Majewska, A; Smyk, JM | 1 |
| El-Hajjaji, F; Katin, KP; Kaya, S; Kochaev, AI; Maslov, MM | 1 |
| Li, Q; Liu, W; Wang, C; Wang, S; Xin, Y | 1 |
| Aoyagi, K; Arakita, K; Banno, S; Doi, Y; Fujisawa, Y; Hase, R; Hattori, H; Ikeda, H; Ikeda, N; Kamio, T; Kasahara, K; Kashizaki, F; Kato, H; Kondo, M; Mitamura, K; Murayama, K; Nakagawa, A; Nishi, K; Ogawa, T; Ohno, Y; Taniguchi, A; Toyama, H | 1 |
| Balboni, A; Campos, JAS; Cilla, D; Finberg, R; Golan, Y; Gonzales-Rojas, Y; Hanabergh, R; Lopez, R; Woolson, R | 1 |
| Itoh, SG; Okumura, H; Tanimoto, S | 1 |
| Atay, E; Bilir, A; Firat, F; Kundakci, YE | 1 |
| Shalhoub, S | 1 |
| Bhavsar, PK; Boffito, M; Caneja, C; Cardoso, SW; Conway, F; Crabtree Ramírez, B; Donaldson, GC; Grinsztejn, B; Johnson, MR; Leaper, C; Mann, B; Orton, CM; Pelly, M; Pozniak, A; Riberio, MPD; Ritchie, AI; Samson, A; Santos, BR; Shah, PL; Tana, A; Tonkin, J; Vijayakumar, B; Wiseman, DJ | 1 |
| Aisyah Rahmania, T; Azzahra Rahmadhani, C; Harahap, Y | 1 |
| Álvarez, G; Cabrera, G; Cerecetto, H; Couto, M; Echeverría, G; Fuentes, G; Gotopo, L; Pezaroglo, H; Piro, O; Romero, AH; Suescun, L | 1 |
| Berber, N; Cagasar, O; Delen, LA; Derya, S; Gok, A; Gok, Z; Kasapoglu, US; Tetik, B | 1 |
| Li, J; Qi, C; Shen, L; Wang, Y; Zhang, Q | 1 |
| Dong, L; Gao, J; Hu, S | 1 |
| Duan, Y; Zhou, C; Zhu, HL | 1 |
| Jensen, JD; Lynch, M | 1 |
| Chan, MCW; Chen, D; Cheung, PP; Choy, KT; Chu, DKW; Huang, X; Hui, KPY; Kaewpreedee, P; Peiris, M; Sia, SF; Wong, AY; Yen, HL | 1 |
| Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
| Şimşek Yavuz, S; Ünal, S | 1 |
| Costanzo, M; De Giglio, MAR; Roviello, GN | 1 |
| Hsueh, PR; Jean, SS; Lee, PI | 1 |
| Ge, J; Li, H; Liu, Z | 1 |
| Alkindi, N; Mazer-Amirshahi, M; Mehta, N; Pourmand, A | 1 |
| Ahsan, W; Alhazmi, HA; Bratty, MA; Javed, S; Najmi, A | 1 |
| Chong, EA; Davids, MS; Mato, AR; Roeker, LE; Schuster, SJ; Shadman, M | 1 |
| de Lamballerie, X; Eloy, P; Guedj, J; Malvy, D; Mentré, F; Solas, C; Touret, F | 1 |
| Chen, XP; Du, YX | 1 |
| Delang, L; Neyts, J | 1 |
| Lin, SX; Stephen, P; Thériault, JF; Wang, R; Zhang, WF | 1 |
| Baggett, MV; Rhee, EP; Shepard, JO; Sise, ME; Stevens, JS | 1 |
| Coomes, EA; Haghbayan, H | 1 |
| Bhalla, S; Gabrilove, J; Sigel, K; Thibaud, S; Tremblay, D; Zimmerman, B | 1 |
| Alper, S; Altuğ, E; Çelebi, İ; Demirkesen, C; Ferhanoğlu, B; Kocatürk, E; Taşkın, B; Vural, S | 1 |
| Eto, M; Fujita, H; Hashida, T; Ikesue, H; Irie, K; Muroi, N; Nakagawa, A; Tamura, R; Tomii, K | 1 |
| Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P | 1 |
| Campos, L; Gouveia, CC | 1 |
| Li, J; Wang, G; Wu, Z; Zhang, C; Zhao, H | 1 |
| Baselga, J; Chung, KK; Collen, J; Desai, JV; Goy, A; Hamdy, A; Izumi, R; Lionakis, MS; Monticelli, MA; Roschewski, M; Rose, K; Roshon, M; Roswarski, J; Sharman, JP; Staudt, LM; Wilson, WH; Wright, GW; Wrzesinski, SH; Zarakas, MA | 1 |
| Chen, D; Dong, L; Pan, X; Peng, C; Yang, L | 1 |
| Abe, T; Anzai, N; Mishima, E; Miyazaki, M | 1 |
| Baker, R; Chavda, N; Clark, F; Fielding, AK; Gupta, R; Khwaja, A; Kottaridis, P; Mansour, MR; O'Nions, J; Payne, E; Subhan, M; Thomson, K; Troy-Barnes, E; Wilson, AJ | 1 |
| Li, C; Ren, L; Wang, L | 1 |
| Fenioux, C; Funck-Brentano, C; Gligorov, J; Gougis, P; Solas, C; Spano, JP; Veyri, M | 1 |
| Ikeda, T; Kondo, Y; Miyazaki, S; Yamashita, R | 1 |
| Martinez, MA | 1 |
| Li, Z; Liu, Y; Wang, D | 1 |
| Ajaz, SJ; Banday, AH; Shameem, SA | 1 |
| Bellutti-Enders, F; Hartmann, K; Jamiolkowski, D; Leuppi-Taegtmeyer, A; Manjaly Thomas, ZR; Scherer Hofmeier, K; Steveling-Klein, E | 1 |
| Carvalho Junior, RN; J C Neto, AM; Martins, AY; Reis, AF; S Costa, JF; Silva Arouche, TD | 1 |
| Han, YJ; Ji, XY; Li, XX; Ma, CY; Ren, ZG; Wu, DD; Yan, JL | 1 |
| Hase, R; Ishida, K; Kurata, R; Kurita, T; Mito, H; Muranaka, E | 1 |
| Carroll, M; Chalmers, JD; De Soyza, A; Dixon, R; Doherty, J; Duncan, G; Felton, T; Gordon, A; Griffiths, G; Ho, LP; Lewis, KE; Martinez-Alier, N; McGarvey, L; O'Kelly, M; Page, C; Phekoo, K; Read, RC; Shankar-Hari, M; Singh, D; Summers, C; Sykes, J; Walles, R; Wilkinson, T | 1 |
| Arab-Zozani, M; Ghoddoosi-Nejad, D; Hassanipour, S | 1 |
| Deshpande, GA; Kaname, S; Kishimoto, M; Komagata, Y; Kurai, D; Ono, K; Shimasaki, T; Uchida, H | 1 |
| Al-Yamani, MJ; Asdaq, SMB; Jomah, S | 1 |
| Ijaz, M; Khan, M; Kharaba, ZJ; Murtaza, G; Shamim, S | 1 |
| Aktaş, A; Aslan, R; Ataseven, H; Sayin, K; Tüzün, B | 1 |
| Hifumi, T; Ishimatsu, S; Isokawa, S; Otani, N | 1 |
| Acar, T; Ari, A; Bozaci, I; Karatas, M; Simsek, C; Tatar, E; Uslu, A; Yildirim, AM; Yildirim, O | 1 |
| Inoue, KI; Sagawa, T; Takano, H | 1 |
| Ershler, WB; Holbrook, ME | 1 |
| Fujii, H; Hiraoka, N; Horiguchi, M; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T | 1 |
| Islam, MA; Nasir, M; Perveen, RA; Saha, SK; Selina, F; Talha, KA | 1 |
| Barfuss, P; Demirbag, S; Khan, KS; Le, TK; Ng, WL; Paris, C; Robson, F; Rocchi, P | 1 |
| Aykaç, K; Cengiz, AB; Ceyhan, M; Cura Yayla, BC; Derin Oygar, P; İlbay, S; Karahan, S; Kukul, MG; Laçinel Gürlevik, S; Özsürekçi, Y | 1 |
| Chae, H; Jeong, HJ; Jeong, K; Kim, S; Lee, G; Min, S; Namgoong, SK | 1 |
| Dauby, N; Konopnicki, D; Roman, A; Van Praet, S; Vanhomwegen, C; Veliziotis, I | 1 |
| Chachaima-Mar, J; Pérez-Castilla, J | 1 |
| Baba, T; Hagiwara, E; Higa, K; Ikeda, S; Iwasawa, T; Kaneko, T; Kitamura, H; Kitayama, T; Komatsu, S; Murohashi, K; Nakazawa, A; Niwa, T; Oda, T; Ogura, T; Okabayashi, H; Okuda, R; Otoshi, R; Sato, Y; Sekine, A; Shintani, R; Yamaya, T | 1 |
| Fukui, Y; Hatano, T; Kawagishi, T; Kawasuji, H; Kuwano, H; Miyajima, Y; Morinaga, Y; Okudera, H; Sakamaki, I; Shibuya, T; Takegoshi, Y; Tani, H; Ueno, A; Wakasugi, M; Yamamoto, Y | 1 |
| Goto, Y; Hiraiwa, H; Ishimoto, T; Jingushi, N; Kato, I; Koshi, E; Kosugi, T; Maruyama, S; Miyagawa, Y; Numaguchi, A; Okazaki, M; Ozaki, M; Saito, S; Tetsuka, N; Toyama, Y; Yagi, T; Yamamoto, T | 1 |
| Canard, B; Coutard, B; Decroly, E; Fattorini, V; Ferron, F; Huchting, J; Le, NT; Meier, C; Peersen, O; Piorkowski, G; Selisko, B; Shannon, A; Touret, F | 1 |
| Banno, S; Doi, Y; Hase, R; Hibino, M; Hirose, M; Homma, Y; Horiguchi, T; Ikeda, N; Imai, T; Iwata, M; Kabata, D; Kamio, T; Kasahara, H; Kasamatsu, Y; Kashizaki, F; Kato, H; Kato, Y; Kita, T; Koba, H; Kodama, N; Kondo, M; Koseki, T; Lim, CK; Maeki, T; Matsuyama, A; Miyata, M; Mutoh, Y; Nakagawa, A; Nakatsumi, H; Nakayama, E; Ogawa, T; Saijo, M; Shinoda, M; Shintani, A; Tajima, S; Taniguchi, S; Terada, M; Teramachi, M; Uchida, Y; Yamamoto, M; Yokota, K; Yokoyama, T; Yoshida, H; Yoshida, J; Yuzawa, Y | 1 |
| Aydın, A; Çekiç, D; Dheir, H; Genc, AB; Karabay, O; Kocayigit, H; Koroglu, M; Şenocak, D; Varım, C; Yaylaci, S | 1 |
| Altın, S; Barça, T; Bolat, E; Fikri, Bİ; Sokucu, SN; Toptaş, M; Tural Onur, S | 1 |
| McCullough, PA | 1 |
| Budhathoki, P; Khadka, S; Pokharel, N; Rashmi, P; Shah, PB; Shrestha, DB | 1 |
| Cao, R; Fu, D; Li, W; Wen, J; Zhao, L; Zhong, W | 1 |
| Emanuela, C; Francesco, L; Giorgia, G; Pasquale, N; Roberto, P; Sara, D | 1 |
| Abe, S; Fujimori, D; Kaizuka, H; Otsuki, S; Takeuchi, Y; Takoi, H; Togashi, Y; Wada, T | 1 |
| Guan, W; Lan, W; Ou, J; Wu, J; Wu, X; Yan, Y; Zhang, J; Zhang, Q; Zhao, S | 1 |
| Hirai, D; Seta, K; Yamashita, D | 1 |
| Aykac, K; Ceyhan, M; Ozsurekci, Y; Yayla, BCC | 1 |
| Abdelaziz, MR; Abu-Melha, S; Edrees, MM; Elfiky, AA; Gomha, SM; Riyadh, SM | 1 |
| Anglaret, X; Binquet, C; Bouchet, S; Crémer, A; Darnaud, T; Dupouy, J; Duvignaud, A; Gimbert, A; Joseph, JP; Journot, V; Lebeaux, D; Lebel, J; Lefèvre, B; Lhomme, E; Malvy, D; Michel, JF; Nguyen, D; Onaisi, R; Orne-Gliemann, J; Peiffer-Smadja, N; Piroth, L; Pistone, T; Poitrenaud, D; Richert, L; Roussillon, C; Sitta, R; Thiébaut, R; Wittkop, L | 1 |
| Cheng, A; Gardiner, B; Hoy, JF; Lau, JSY; Lee, SJ; McMahon, JH; Molton, JS; Peleg, AY; Rogers, BA; Roney, J; Sasadeusz, J; Trubiano, J | 1 |
| Dauby, N | 1 |
| Ban, K; Choi, SW; Go, YY; Jung, E; Kim, SJ; Lee, J; Lee, JH; Moon, SH; Park, HJ; Park, SJ; Park, SM; Park, YG; Shin, JS | 1 |
| Boretti, A | 1 |
| Bazram, A; Fathalipour, M; Hassaniazad, M; Hassanipour, S | 1 |
| He, L; Hu, X; Liang, T; Liu, L; Lou, Y; Lu, X; Luo, R; Qiu, Y; Su, J; Xu, K; Yang, X; Yao, H; Zhao, Q | 1 |
| Ardjmand, M; Esfahani, MR; Khodashenas, B; Rad, AS | 1 |
| Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Kastritis, E; Korompoki, E; Migkou, M; Ntanasis-Stathopoulos, I; Psaltopoulou, T; Terpos, E; Tzanninis, IG | 1 |
| Demir, G; Dheir, H; Erdem, AF; Güçlü, E; Kocayiğit, H; Özmen Süner, K; Tomak, Y; Yaylacı, S | 1 |
| Alaskar, A; Aldibasi, O; Alharbi, A; Aljeraisy, M; AlJohani, S; Almaghaslah, M; Almutairi, B; Alothman, A; Alqahtani, H; Alsaedy, A; Arabi, Y; Bosaeed, M; Bouchama, A; Hussein, M; Mahmoud, E; Nashabat, M | 1 |
| Ansari, A; Barkate, H; Joshi, S; Parkar, J; Patil, S; Talwar, D; Tiwaskar, M; Vora, A | 1 |
| Vaidyanathan, G | 1 |
| Ghasemnejad-Berenji, M; Pashapour, S | 1 |
| Al Bahrani, M; Al Balushi, Z; Al Barwani, U; Al Lawati, A; Al Naabi, H; Al Salmi, I; Al Sharji, M; Al-Zakwani, I; Ambusaidi, Z; Khamis, F; Pandak, N | 1 |
| Hase, R; Ishida, K; Kurita, T; Mito, H; Muranaka, E; Sasazawa, H; Yano, Y | 1 |
| Çağlayan, D; Erdem, HA; Gökengin, D; Işıkgöz Taşbakan, M; Korkma, PE; Sayıner, A; Taşbakan, MS; Yamazhan, T | 1 |
| Mishra, SK; Tripathi, T | 1 |
| Boku, R; Hirouchi, T; Iwata, K; Kamachi, K; Mashima, D; Matsumoto, T; Morikawa, M; Ota, S; Sato, T; Shinada, K; Shinkai, M; Shinoda, M; Yoshida, Y | 1 |
| Holland, TL | 1 |
| Korman, TM | 1 |
| Chao, CM; Chen, PJ; Lai, CC | 1 |
| Ambrosino, I; Barbagelata, E; Ciarambino, T; Corbi, G; Moretti, AM; Politi, C | 1 |
| Govil, A; Luckett, K; Miller-Handley, H | 1 |
| Durvasula, R; Durvasula, SR; Kunamneni, A; Maciorowski, D; Ogaugwu, C | 1 |
| Macip, S; Massip-Salcedo, M; Qusairy, Z; Rada, M | 1 |
| Habib, AA; Hammad, SF; Kamal, AH; Megahed, SM | 1 |
| Kumar, D; Trivedi, N; Verma, A | 1 |
| Atsumi, T; Cho, KY; Inoshita, N; Kamada, K; Kameda, H; Kenmotsu, Y; Konno, S; Miyoshi, H; Nakakubo, S; Nakamura, A; Nakamura, J; Nomoto, H; Sawamura, Y; Shimatsu, A; Sugino, H; Suzuki, M; Takahashi, Y; Yamashita, Y; Yuno, A | 1 |
| Chakraborty, U; Chandra, A; Ghosh, S; Ray, AK | 1 |
| Chen, G; Chen, X; Li, J; Qin, Y; Wang, G; Wang, K; Wei, M; Wu, Z; Yu, J; Zhang, C; Zhao, H; Zhu, Q | 1 |
| Boku, R; Hirouchi, T; Iwata, K; Kamachi, K; Matsumoto, T; Morikawa, M; Ota, S; Sato, T; Shinada, K; Shinkai, M; Shinoda, M; Yoshida, Y; Yoshimatsu, L | 1 |
| Igari, H; Ishii, I; Nakada, TA; Sayama, M; Suzuki, T; Yamazaki, S | 1 |
| Akdeniz, N; Aksoy, H; Aslan Kayıran, M; Cebeci, F; Erdemir, VA; Gürel, MS | 1 |
| da Silva, S; Martinková, I; Petroušová, L; Rožnovský, L | 1 |
| Wen, S; Xu, X; Yadav, AK; Yu, L | 1 |
| Benner, B; Carson, WE | 1 |
| Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M | 1 |
| Kutlu, Ö; Yılmaz, Ş | 1 |
| Abou-Sleymane, G; Al Faraj, A; Badro, DA; Daou, F; Khanafer, N; Tobaiqy, M | 1 |
| Brügel, M; Habler, K; Liebchen, U; Paal, M; Scharf, C; Schönermarck, U; Teupser, D; Vogeser, M | 1 |
| Bermejo, F; Bernal-Bello, D; Duarte-Millán, MÁ; Farfán-Sedano, AI; Frutos-Pérez, B; García-Gil, M; García-Parra, CJ; Gonzalo-Pascua, S; Hernández-Muniesa, B; Jaenes-Barrios, B; Madroñal-Cerezo, E; Morales-Ortega, A; Ontañón-Nasarre, A; Rivas-Prado, L; Ruiz-Giardín, JM; San Martín-López, JV | 1 |
| Danduga, RCSR; James, RA; Kandaswamy, DK; Raj, CTD; Rajasabapathy, R | 1 |
| Igari, H; Ikusaka, M; Kasai, H; Sakao, S; Shimada, R; Takayanagi, S; Taniguchi, T; Tawara, J; Uehara, T; Yahaba, M | 1 |
| Uslu, S | 1 |
| Barkate, H; Caracta, CF; Patil, S; Rangwala, S; Tandon, M; Udwadia, ZF; Wu, W | 1 |
| Medisetty, MK; Patel, A; Pujari, S | 1 |
| Moriiwa, Y; Morikawa, G; Okazawa, K; Yanagida, A | 1 |
| Adcock, IM; Bassir, A; Dalil Roofchayee, N; Dezfuli, NK; Jamaati, H; Marjani, M; Mehrian, P; Moniri, A; Mortaz, E; Mumby, S; Rezaei, M; Tabarsi, P; Varahram, M | 1 |
| Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S | 1 |
| Alotaibi, NH; Bokharee, N; Khan, YH; Khokhar, A; Mallhi, TH; Rasheed, M | 1 |
| Barthélémy, K; Cochin, M; Coutard, B; de Lamballerie, X; Driouich, JS; Guedj, J; Laprie, C; Lingas, G; Moureau, G; Nougairède, A; Petit, PR; Piorkowski, G; Solas, C; Touret, F | 1 |
| Oruç, MA; Öz, H; Öztürk, O | 1 |
| Fukui, Y; Kaneda, M; Kawago, K; Kawasuji, H; Kimoto, K; Miyajima, Y; Morinaga, Y; Murai, Y; Ogami, C; Sakamaki, I; Takegoshi, Y; Tsuji, Y; Ueno, A; Yamamoto, Y | 1 |
| Arumugaswami, V; Bakowski, MA; Bartenschlager, R; Beck, S; Betz, UAK; Beutler, N; Chatterjee, AK; Damoiseaux, RD; Gabriel, G; Garcia, G; Gomperts, B; Han, B; Kim, H; Kirkpatrick, MG; Kohn, DB; Parcells, MS; Purbey, PK; Purkayastha, A; Ramaiah, A; Riva, L; Rogers, TF; Scumpia, P; Sen, C; Sharma, A; Svendsen, CN; Ulmert, D; Wolff, KC; Yuen, C | 1 |
| Dabbous, HM; Ebeid, FFS; El Assal, G; El-Sayed, MH; Elgaafary, M; Elghazaly, H; Fawzy, E; Hassany, SM; Riad, AR; Sherief, AF; TagelDin, MA | 1 |
| Fujii, H; Goda, S; Hiraoka, N; Matsumoto, Y; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Sugitani, M; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T | 1 |
| Fujita, N; Ito, T; Kasamatsu, Y; Kunimitsu, K; Matsubara, S; Munakata, N; Sasao, A; Tsuboi, H; Tsuchido, Y; Yamawaki, M | 1 |
| Kami, M; Murayama, A; Ozaki, A; Tanimoto, T; Ueda, M | 1 |
| Abraham, I; Al-Jedai, A; Alajami, HN; Alali, AH; Alamer, A; Alfaifi, M; AlHassar, F; Alkharji, F; Almulhim, AS; Almutairi, M; Almutairi, W; Alosaimi, B; Alrashed, AA; Alsaeed, A; Baredhwan, AA; Howaidi, J; Mohzari, Y; Sulaiman, T | 1 |
| Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W | 1 |
| Fujii, S; Fujiya, Y; Fukudo, M; Ibe, Y; Inamura, H; Ishigo, T; Kunimoto, Y; Kuronuma, K; Nakata, H; Takahashi, S | 1 |
| Caferoğlu Sakat, S; Metin, N; Turan, Ç; Utlu, Z; Yıldız, TT | 1 |
| Chang, X; Chen, G; Chen, X; Du, W; Gong, B; Ji, Y; Jiang, X; Jiang, Y; Li, G; Li, J; Li, N; Li, W; Liu, Y; Peng, P; Sun, W; Wang, G; Wang, Y; Wu, Z; Xiao, Z; Yao, J; Zeng, Q; Zhang, C; Zhao, H; Zhu, F; Zhu, Q | 1 |
| Avcı, İY; Çetinkaya, RA; Demirtürk, N; Eser, F; Güner, R; Karalezli, A; Kayaaslan, B; Konya, P; Okumuş, N; Orhan, S; Savaşçı, Ü; Şaylan, B; Taşkın, G; Yamanel, L; Yılmaz, G | 1 |
| Demir, G; Dheir, H; Erdem, AF; Kalpakci, Y; Karacan, A; Kocayiğit, H; Süner, KÖ; Tomak, Y; Yaylacı, S | 1 |
| Gülseren, D; Yalıcı-Armagan, B | 1 |
| Indira, P; Md Nayeem, S; Sohail, EM; Srihari, NV; Srinivasa Reddy, M | 1 |
| Fukuoka, S; Imai, T; Kishaba, T; Maeda, A; Nabeya, D; Nagano, H; Narita, M; Shiiki, S; Takakura, S; Yokoyama, S | 1 |
| Bayrakci, B; Cengiz, AB; Gülhan, B; Gürlevik, SL; Kesici, S; Kurt Sukur, ED; Oygar, PD; Ozen, S; Ozsurekci, Y; Topaloglu, R | 1 |
| Akgun, H; Avci, D; Bilgin, M; Cerci, P; Efe, S; Ozmen, A; Ucan, A; Yagmuroglu, A | 1 |
| Amani, B; Arab-Zozani, M; Fathalipour, M; Hassanipour, S; Heidarzad, F; Martinez-de-Hoyo, R | 1 |
| Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D | 1 |
| Abusoglu, S; Eryavuz Onmaz, D; Onmaz, M; Unlu, A; Yerlikaya, FH | 1 |
| Alkan, G; Artac, H; Emiroglu, M; Oz, SKT | 1 |
| Khoo, SH; Owen, A; Pertinez, H; Rajoli, RKR | 1 |
| Aktaş, A; Albayrak, İD; Hayran, Y; Öcalan, DT | 1 |
| Altun, D; Ömeroğlu, ŞK; Öztop, B; Temel, F | 1 |
| Doi, Y; Ide, T; Imai, T; Komoto, S; Lim, CK; Murata, T; Sakurai, A; Shintani, A; Suzuki, M | 1 |
| Hashemian, SM; Khoundabi, B; Velayati, AA | 1 |
| Kulkarni, A; Nasa, P; Shrivastava, P; Singh, A; Vijayan, L | 1 |
| Kundu, S; Sarkar, D | 1 |
| Demir, B; Demir, E; Sütcüoğlu, O; Ünsal, O; Yazıcı, O | 1 |
| Ayıntap, E; Aytogan, H; Doran, MA | 1 |
| Eto, M; Fujita, H; Fukushima, S; Hashida, T; Ikesue, H; Irie, K; Muroi, N; Nakagawa, A; Tamura, R; Tomii, K | 1 |
| Arditi, M; Arumugaswami, V; Bahar, I; Chan, SY; Chen, F; Cheng, MH; Garcia, G; Gomez, AC; Liu, B; Pei, F; Porritt, RA; Schurdak, ME; Shi, Q; Stern, AM; Taylor, DL; Vogt, A | 1 |
| Akcan, RE; Ergönül, Ö; Gönen, M; Kalender, M; Keske, Ş; Kozan, Ş; Özlüşen, B; Peltek, İB; Yaprak, D | 1 |
| Berk, H; Demir Önder, K; Öztoprak, N; Seremet Keskin, A; Seyman, D | 1 |
47 review(s) available for pyrazines and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Future of antivirals in COVID-19: The case of favipiravir.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Pyrazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2022 |
Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
Topics: Adenosine Monophosphate; Alanine; Amides; Catalytic Domain; Computational Biology; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Pyrazines; Pyrimidines; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Triazoles; Virus Replication | 2022 |
State-of-the-Art Molecular Dynamics Simulation Studies of RNA-Dependent RNA Polymerase of SARS-CoV-2.
Topics: Adenosine Triphosphate; Amides; Antiviral Agents; COVID-19; Humans; Ligands; Lysine; Molecular Docking Simulation; Molecular Dynamics Simulation; Pyrazines; RNA; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2022 |
Clinical trial analysis of 2019-nCoV therapy registered in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Disease Management; Disease Outbreaks; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Pyrazines; SARS-CoV-2 | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Thiazoles | 2020 |
Treatment options for COVID-19: The reality and challenges.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Teicoplanin | 2020 |
Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Testing; COVID-19 Vaccines; Disease Progression; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunization, Passive; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severity of Illness Index; Spike Glycoprotein, Coronavirus; Viral Vaccines | 2020 |
Pharmacotherapy in COVID-19; A narrative review for emergency providers.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Emergency Service, Hospital; Humans; Hydroxychloroquine; Interleukin-6; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2 | 2020 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferon-alpha; Interferon-beta; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Medical treatment options for COVID-19.
Topics: Adenosine Monophosphate; Administration, Intravenous; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Cytochrome P-450 CYP3A Inhibitors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Recombinant Proteins; RNA, Viral; SARS-CoV-2 | 2020 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Coronavirus Disease 2019: Clinical Review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus; Blood Coagulation Disorders; China; Chiroptera; Chloroquine; Coronavirus Infections; COVID-19; Glucocorticoids; Humans; Hydroxychloroquine; Infectious Disease Incubation Period; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Prognosis; Pyrazines; Radiography, Thoracic; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Symptom Assessment | 2020 |
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Interferons; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis | 2020 |
Uric Acid Elevation by Favipiravir, an Antiviral Drug.
Topics: Aldehyde Oxidase; Amides; Antiviral Agents; Biotransformation; Coronavirus Infections; COVID-19; Drug Interactions; Humans; Hyperuricemia; Kidney; Kidney Diseases; Molecular Structure; Organic Anion Transport Protein 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Pandemics; Pneumonia, Viral; Pyrazines; Uric Acid; Xanthine Oxidase | 2020 |
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Teicoplanin | 2020 |
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Administration Schedule; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis; Treatment Outcome | 2020 |
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Topics: Adenosine Monophosphate; Alanine; Amides; Angiotensin-Converting Enzyme Inhibitors; Antimalarials; Antiviral Agents; Betacoronavirus; Biomedical Research; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Drug Combinations; Drug Development; Drugs, Chinese Herbal; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Drug Hypersensitivity; Humans; Immunity, Innate; Immunologic Factors; Indoles; Infliximab; Interleukin 1 Receptor Antagonist Protein; Nitriles; Pandemics; Pneumonia, Viral; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2; Severity of Illness Index | 2020 |
Advances and challenges in the prevention and treatment of COVID-19.
Topics: Amides; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Chloroquine; Chlorpromazine; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cyclophilins; Drug Development; Drug Repositioning; Drugs, Chinese Herbal; Endocytosis; Humans; Immune Sera; Interferon Inducers; Nucleic Acid Synthesis Inhibitors; Pandemics; Pneumonia, Viral; Pyrazines; Resveratrol; SARS-CoV-2; Viral Vaccines | 2020 |
Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Potential strategies for combating COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; COVID-19 Vaccines; Cytokine Release Syndrome; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Indoles; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Severity of Illness Index; Viral Vaccines | 2020 |
High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.
Topics: Aged; Amides; Antibodies, Antinuclear; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Glucocorticoids; Guanidines; Humans; Hydroxychloroquine; Lung Diseases, Interstitial; Male; Methylprednisolone; Pandemics; Pneumonia, Viral; Pregnenediones; Pyrazines; Recovery of Function; Respiratory Distress Syndrome; Respiratory Insufficiency; SARS-CoV-2; Severity of Illness Index; Tomography, X-Ray Computed | 2020 |
Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
Topics: Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Treatment Outcome | 2020 |
Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Cytidine; Genome, Viral; Humans; Hydroxylamines; Molecular Targeted Therapy; Mutation; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleosides; RNA, Viral; SARS-CoV-2; Severity of Illness Index; Transcription, Genetic; Viral Nonstructural Proteins; Virus Replication | 2020 |
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Databases, Factual; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Humans; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Standard of Care; Treatment Outcome | 2020 |
Current treatment of COVID-19 in renal patients: hope or hype?
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal; Cobicistat; Coronavirus Infections; COVID-19; Darunavir; Drug Combinations; Humans; Kidney; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ritonavir | 2020 |
COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antibodies, Viral; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Repositioning; Humans; Immunization, Passive; Medicine, Chinese Traditional; Pandemics; Pyrazines; SARS-CoV-2; World Health Organization | 2020 |
Favipiravir use for SARS CoV-2 infection.
Topics: Amides; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Pyrazines; SARS-CoV-2; Treatment Outcome | 2020 |
Emerging treatment strategies for COVID-19 infection.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Humans; Hydroxychloroquine; Immunization, Passive; Palliative Care; Pyrazines; SARS-CoV-2; Treatment Outcome | 2021 |
Role of favipiravir in the treatment of COVID-19.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pyrazines; SARS-CoV-2 | 2021 |
Favipiravir and COVID-19: A Simplified Summary.
Topics: Amides; Antiviral Agents; Clinical Trials as Topic; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Humans; Mutagenesis; Pyrazines; RNA, Viral; SARS-CoV-2; Treatment Outcome | 2021 |
One year update on the COVID-19 pandemic: Where are we now?
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Drug Combinations; Drug Repositioning; Glucocorticoids; Humans; Hydroxychloroquine; Indoles; Ivermectin; Lopinavir; Mutation; Pandemics; Phytotherapy; Plant Extracts; Pyrazines; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tinospora; Viral Zoonoses | 2021 |
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Creatinine; Cytidine; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Hydroxylamines; Immunization, Passive; Interferons; Janus Kinase Inhibitors; Lopinavir; Pyrazines; Renal Elimination; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dexamethasone; Humans; Immunization, Passive; Pyrazines; SARS-CoV-2; Viral Proteins | 2021 |
Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antiviral Agents; Benzamides; COVID-19; COVID-19 Drug Treatment; Humans; Lung; Molecular Targeted Therapy; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrazines; Thrombosis | 2021 |
Possible treatment and strategies for COVID-19: review and assessment.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiparasitic Agents; Antiviral Agents; Cannabinoids; Chloroquine; Complement Inactivating Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Pyrazines; Ritonavir; SARS-CoV-2; Teicoplanin; Tetracyclines; Thiazoles | 2020 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles | 2021 |
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Databases, Factual; Humans; Hydroxychloroquine; Immunoglobulins; Lopinavir; Pandemics; Pyrazines; Respiration, Artificial; Ritonavir; SARS-CoV-2 | 2021 |
The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Pandemics; Pyrazines | 2021 |
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Serotherapy; Dexamethasone; Drug Repositioning; Evolution, Molecular; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Phylogeny; Prospective Studies; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2021 |
[The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Combined Modality Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Lopinavir; Mesenchymal Stem Cell Transplantation; Pandemics; Pyrazines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Treatment Outcome; Uncertainty | 2021 |
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Intensive Care Units; Length of Stay; Lopinavir; Methylprednisolone; Observational Studies as Topic; Patient Admission; Pyrazines; Ritonavir; SARS-CoV-2; Survival Rate | 2021 |
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
Topics: Amides; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Intensive Care Units; Pyrazines; SARS-CoV-2; Survival Analysis; Treatment Outcome; Viral Load | 2021 |
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inducers; Dexamethasone; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Epilepsy; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Ivermectin; Lopinavir; Pyrazines; Ritonavir; SARS-CoV-2 | 2021 |
Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Lopinavir; Pyrazines; SARS-CoV-2 | 2022 |
Effectiveness of favipiravir in COVID-19: a live systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; Male; Middle Aged; Observational Studies as Topic; Pyrazines; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Young Adult | 2021 |
20 trial(s) available for pyrazines and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19.
Topics: Azetidines; Clinical Trials, Phase II as Topic; COVID-19; Diabetes Mellitus, Type 2; Humans; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; State Medicine; Treatment Outcome | 2021 |
The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.
Topics: Adenosine Monophosphate; Alanine; Amides; Antioxidants; Antiviral Agents; Biomarkers; COVID-19; COVID-19 Drug Treatment; Drug Monitoring; Female; Hemoglobins; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Patient Discharge; Pyrazines; Quercetin; Respiratory Rate | 2022 |
Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect.
Topics: Algorithms; Amides; Artificial Intelligence; COVID-19; Humans; Lung; Prospective Studies; Pyrazines; SARS-CoV-2; Tomography, X-Ray Computed | 2022 |
Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care.
Topics: Adult; Aged; COVID-19; Humans; Middle Aged; Pyrazines; SARS-CoV-2; Treatment Outcome | 2023 |
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.
Topics: Adult; Aged; Amides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intubation, Gastrointestinal; Male; Pandemics; Pneumonia, Viral; Pyrazines; Respiration, Artificial; SARS-CoV-2; Severity of Illness Index; Suspensions; Tablets; Treatment Outcome | 2020 |
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; RNA, Viral; SARS-CoV-2; Treatment Outcome; Young Adult | 2020 |
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised
Topics: Antiviral Agents; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hospitalization; Humans; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Standard of Care | 2020 |
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Asymptomatic Diseases; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Hyperuricemia; Japan; Male; Middle Aged; Prospective Studies; Pyrazines; Random Allocation; SARS-CoV-2; Secondary Prevention; Severity of Illness Index; Time-to-Treatment; Treatment Outcome; Viral Load | 2020 |
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to R
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Tolerance; Feasibility Studies; France; Hospitalization; Humans; Hydroxychloroquine; Imatinib Mesylate; Luxembourg; Outpatients; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Risk Reduction Behavior; SARS-CoV-2; Telmisartan; Therapies, Investigational; Treatment Outcome | 2020 |
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
Topics: Amides; Antiviral Agents; Australia; Betacoronavirus; Biomarkers; Clinical Protocols; Coronavirus Infections; COVID-19; Female; Hospitalization; Humans; Male; Pandemics; Placebos; Pneumonia, Viral; Pyrazines; Safety; SARS-CoV-2; Treatment Outcome | 2020 |
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Topics: Adult; Amides; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Interferons; Iran; Lopinavir; Male; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Viral Load | 2020 |
Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Dibenzothiepins; Drug Monitoring; Female; Humans; Inhibitory Concentration 50; Male; Middle Aged; Morpholines; Pyrazines; Pyridones; SARS-CoV-2; Symptom Assessment; Treatment Outcome; Triazines; Viral Load | 2021 |
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Topics: Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Inpatients; Male; Multicenter Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Saudi Arabia; Time Factors; Treatment Outcome | 2020 |
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.
Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine; Interferon beta-1b; Male; Middle Aged; Pyrazines; SARS-CoV-2; Treatment Outcome | 2021 |
Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Humans; Interleukin-6; Kaplan-Meier Estimate; Lung; Male; Middle Aged; Models, Immunological; Pyrazines; Receptors, Interleukin-6; Respiration, Artificial; Sample Size; SARS-CoV-2; Treatment Outcome | 2021 |
Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
Topics: Adult; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Ferritins; Fibrin Fibrinogen Degradation Products; Humans; Hydroxychloroquine; Male; Middle Aged; Oseltamivir; Pyrazines; Treatment Outcome | 2021 |
Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
Topics: Administration, Oral; Adult; Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; Lymphocyte Subsets; Male; Middle Aged; Patient Discharge; Pyrazines; Reinfection; RNA, Viral; SARS-CoV-2; Treatment Outcome | 2021 |
Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.
Topics: Aged; Amides; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; Azithromycin; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Ivermectin; Male; Middle Aged; Pneumonia, Viral; Prospective Studies; Pyrazines; Single-Blind Method; Treatment Outcome | 2021 |
Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
Topics: Acute Kidney Injury; Adenosine Monophosphate; Adolescent; Alanine; Amides; Child; COVID-19; COVID-19 Drug Treatment; Creatinine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Male; Pyrazines; Renal Elimination; SARS-CoV-2; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2021 |
Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.
Topics: Amides; Antiviral Agents; China; COVID-19; Europe; Genomics; Humans; Japan; Male; Pyrazines; SARS-CoV-2; Treatment Outcome | 2021 |
130 other study(ies) available for pyrazines and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study.
Topics: Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; Retrospective Studies; SARS-CoV-2; Standard of Care; Treatment Outcome | 2021 |
Favipiravir Induced Nephrotoxicity in two Patients of COVID-19.
Topics: Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; SARS-CoV-2; Treatment Outcome | 2021 |
Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave.
Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Azithromycin; C-Reactive Protein; Comorbidity; COVID-19; COVID-19 Drug Treatment; Critical Care; Drug Combinations; Enoxaparin; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Lopinavir; Male; Methylprednisolone; Middle Aged; Pyrazines; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Turkey | 2022 |
Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
Topics: Adult; Amides; Azithromycin; Child; COVID-19; Hematologic Neoplasms; Humans; Hydroxychloroquine; Pyrazines; SARS-CoV-2; Turkey | 2022 |
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
Topics: Amides; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytidine; Disease Models, Animal; Drug Therapy, Combination; Female; Hydroxylamines; Lung; Mesocricetus; Pyrazines; RNA, Viral; Treatment Outcome; Viral Load | 2021 |
Effect of drug metabolism in the treatment of SARS-CoV-2 from an entirely computational perspective.
Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Design; Drug Discovery; Humans; Metabolic Networks and Pathways; Molecular Docking Simulation; Nitro Compounds; Pyrazines; Pyrrolidines; Ribavirin; SARS-CoV-2; Thiazoles | 2021 |
Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: A case-series study.
Topics: Amides; Antiviral Agents; COVID-19; Humans; Minocycline; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome | 2022 |
The relationship between Covid-19 and mucociliary clearance.
Topics: Adrenal Cortex Hormones; Adult; Amides; Antiviral Agents; Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Length of Stay; Male; Middle Aged; Mucociliary Clearance; Nasal Mucosa; Pyrazines; Smoking | 2021 |
African scientists race to test COVID drugs - but face major hurdles.
Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Drug Therapy, Combination; Humans; Hydroxylamines; Imidazoles; Ivermectin; Naphthyridines; Nitro Compounds; Pregnenediones; Pyrazines; Pyrrolidines; Ritonavir; Sample Size; Thiazoles; Valine; World Health Organization | 2021 |
Hematological Malignancy Patients, COVID-19, and Favipiravir
Topics: Amides; COVID-19; Hematologic Neoplasms; Humans; Pyrazines; SARS-CoV-2 | 2021 |
The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behçet's syndrome.
Topics: Adolescent; Adult; Amides; Antiviral Agents; Behcet Syndrome; Comorbidity; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Incidence; Male; Middle Aged; Prospective Studies; Pyrazines; Treatment Outcome; Young Adult | 2022 |
An AGEP case due to COVİD-19 or favipiravir or enoxaparin.
Topics: Amides; COVID-19; Enoxaparin; Humans; Pyrazines; SARS-CoV-2 | 2022 |
An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19.
Topics: Amides; Antiviral Agents; Cornea; COVID-19; Humans; Pyrazines; SARS-CoV-2 | 2021 |
Favipiravir exposure and pregnancy outcome of COVID-19 patients.
Topics: Amides; COVID-19; Female; Humans; Pregnancy; Pregnancy Outcome; Pyrazines; SARS-CoV-2 | 2022 |
Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients.
Topics: Amides; COVID-19; Humans; Hyperuricemia; Pyrazines; SARS-CoV-2; Uric Acid | 2022 |
Letter in response to: Alamer A, Alrashed AA, Alfaifi M, et al. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysi
Topics: Amides; COVID-19; Critical Illness; Humans; Propensity Score; Pyrazines; Retrospective Studies; SARS-CoV-2 | 2022 |
Menthol-assisted homogenous liquid-liquid microextraction for HPLC/UV determination of favipiravir as an antiviral for COVID-19 in human plasma.
Topics: Amides; Antiviral Agents; Chromatography, High Pressure Liquid; COVID-19; COVID-19 Drug Treatment; Humans; Liquid Phase Microextraction; Menthol; Pyrazines; SARS-CoV-2 | 2022 |
Visual classification of three computed tomography lung patterns to predict prognosis of COVID-19: a retrospective study.
Topics: Adult; Aged; Amides; Antiviral Agents; Body Temperature; C-Reactive Protein; COVID-19; COVID-19 Drug Treatment; Female; Fibrin Fibrinogen Degradation Products; Humans; L-Lactate Dehydrogenase; Lung; Lymphocyte Count; Male; Middle Aged; Mucin-1; Neutrophils; Predictive Value of Tests; Prognosis; Pyrazines; Radiographic Image Interpretation, Computer-Assisted; Retrospective Studies; SARS-CoV-2; Steroids; Tomography, X-Ray Computed | 2022 |
Favipiravir Use in Kidney Transplant Recipients with COVID-19: A Single-Center Experience.
Topics: Amides; COVID-19; Female; Humans; Kidney Transplantation; Male; Middle Aged; Pyrazines; Retrospective Studies; SARS-CoV-2; Transplant Recipients; Treatment Outcome | 2022 |
Real-world Experience with Favipiravir for Treatment of COVID-19 among Indian Healthcare Professionals.
Topics: Amides; COVID-19; Cross-Sectional Studies; Delivery of Health Care; Humans; Pyrazines; SARS-CoV-2 | 2022 |
Favipiravir in the Battle with Respiratory Viruses.
Topics: Amides; Animals; Antiviral Agents; COVID-19; Humans; Pyrazines; RNA Viruses; Virus Diseases; Viruses | 2022 |
Ab Initio Insight into the Interaction of Metal-Decorated Fluorinated Carbon Fullerenes with Anti-COVID Drugs.
Topics: Amides; Antiviral Agents; Chloroquine; COVID-19; Density Functional Theory; Drug Carriers; Drug Delivery Systems; Fullerenes; Halogenation; Metals; Models, Molecular; Nickel; Pyrazines | 2022 |
Core-shell nanocomposite of flower-like molybdenum disulfide nanospheres and molecularly imprinted polymers for electrochemical detection of anti COVID-19 drug favipiravir in biological samples.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disulfides; Electrochemical Techniques; Humans; Limit of Detection; Molecularly Imprinted Polymers; Molybdenum; Nanocomposites; Nanospheres; Oxidation-Reduction; Pyrazines; Reproducibility of Results; SARS-CoV-2 | 2022 |
Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial.
Topics: Adult; Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome | 2023 |
Investigation of developmental toxicity of favipiravir on fetal bone and embryonic development.
Topics: Amides; Animals; Antiviral Agents; COVID-19; Embryonic Development; Female; Fetus; Pregnancy; Pyrazines; Rats; Rats, Wistar | 2022 |
PIONEER trial: favipiravir to treat moderate COVID-19.
Topics: Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; Treatment Outcome | 2023 |
HPLC-DAD quantification of favipiravir in whole blood after extraction from volumetric absorptive microsampling devices.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; COVID-19; Humans; Pyrazines | 2023 |
Tautomerism and Rotamerism of Favipiravir and Halogenated Analogues in Solution and in the Solid State.
Topics: Amides; COVID-19; Humans; Pyrazines; Solvents | 2023 |
EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
Topics: Aged; Amides; Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Disease Progression; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pneumonia; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome | 2022 |
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Studies as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Discovery; Humans; Indoles; Pandemics; Pneumonia, Viral; Pyrazines; Ribonucleotides; SARS-CoV-2; Virus Replication | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.
Topics: Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Models, Genetic; Mutation; Mutation Accumulation; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2 | 2020 |
Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimetabolites; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Emetine; Epithelial Cells; Homoharringtonine; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; SARS-CoV-2; Vero Cells; Virus Replication | 2020 |
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Indoles; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Macrophages; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2.
Topics: Amides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus | 2020 |
Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".
Topics: Amides; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus | 2020 |
Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks.
Topics: Adenine; Adenosine; Amides; Antiviral Agents; Betacoronavirus; Binding Sites; Coronavirus Infections; COVID-19; Humans; Molecular Docking Simulation; Nucleotidyltransferases; Pandemics; Pneumonia, Viral; Protein Structure, Tertiary; Pyrazines; Pyrrolidines; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2020 |
Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury.
Topics: Acute Kidney Injury; Adenosine Monophosphate; Aged; Alanine; Amides; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Betacoronavirus; Continuous Renal Replacement Therapy; Coronavirus Infections; COVID-19; Creatinine; Humans; Hypertension; Lung; Male; Obesity; Pandemics; Pneumonia, Viral; Pyrazines; Radiography, Thoracic; SARS-CoV-2 | 2020 |
Favipiravir, an antiviral for COVID-19?
Topics: Amides; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2 | 2020 |
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pandemics; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; SARS-CoV-2 | 2020 |
Coronavirus 19 presenting with atypical Sweet's syndrome.
Topics: Amides; Antibodies, Monoclonal, Humanized; Biopsy, Needle; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Diagnosis, Differential; Erythema; Facial Dermatoses; Female; Fever; Humans; Immunohistochemistry; Middle Aged; Pandemics; Pneumonia, Viral; Pyrazines; Real-Time Polymerase Chain Reaction; Sweet Syndrome; Tomography, X-Ray Computed | 2020 |
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Benzamides; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Illness; Female; Follow-Up Studies; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Monocytes; Pandemics; Pneumonia, Viral; Prospective Studies; Pyrazines; Respiration, Artificial; SARS-CoV-2; Treatment Outcome | 2020 |
Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
Topics: Adult; Aniline Compounds; COVID-19; COVID-19 Drug Treatment; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Pyrazines; Remission Induction; SARS-CoV-2 | 2020 |
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antiviral Agents; Betacoronavirus; Chemical and Drug Induced Liver Injury; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxychloroquine; Immunosuppression Therapy; Kidney Diseases; Long QT Syndrome; Lopinavir; Neoplasms; Pandemics; Pneumonia, Viral; Poly(ADP-ribose) Polymerase Inhibitors; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Coinfection with SARS-CoV-2 and influenza A virus.
Topics: Amides; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Coinfection; Coronavirus Infections; COVID-19; Diagnosis, Differential; Glucocorticoids; Humans; Influenza A virus; Influenza, Human; Lung; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pregnenediones; Pyrazines; Radiography; Real-Time Polymerase Chain Reaction; SARS-CoV-2 | 2020 |
Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cyclopropanes; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Mice, Transgenic; Proline; Pyrazines; SARS-CoV-2; Small Molecule Libraries; Sulfonamides; Vaccines, Synthetic | 2020 |
Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
Topics: Adenine; Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Drug Interactions; Humans; Hydrogen Bonding; Hydroxychloroquine; Ligands; Molecular Docking Simulation; Nanotechnology; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; Pyrrolidines; Ribavirin; SARS-CoV-2; Static Electricity; Viral Nonstructural Proteins | 2020 |
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
Topics: Adult; Amides; Antiviral Agents; Arthritis, Gouty; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hyperuricemia; Lung; Male; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Uric Acid | 2020 |
Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials.
Topics: Adult; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Male; Meta-Analysis as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Research Design; SARS-CoV-2; Systematic Reviews as Topic; Treatment Outcome | 2020 |
Reactive arthritis after COVID-19 infection.
Topics: Adrenal Cortex Hormones; Amides; Ankle Joint; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthritis, Reactive; Arthrocentesis; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Injections, Intra-Articular; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prohibitins; Pyrazines; Respiration, Artificial; Respiratory Distress Syndrome; SARS-CoV-2 | 2020 |
New anti-viral drugs for the treatment of COVID-19 instead of favipiravir.
Topics: Amides; Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Pharmaceutical Preparations; Pyrazines; SARS-CoV-2 | 2021 |
Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Guanidines; Humans; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2 | 2020 |
Intravenous Immunoglobulin and Favipiravir treatment for A Kidney Transplant Patient with Severe Covid-19 Pneumonia.
Topics: Aged; Amides; COVID-19; COVID-19 Drug Treatment; Female; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Kidney Transplantation; Pneumonia; Pyrazines; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illness; Disease Progression; Guanidines; Humans; Pandemics; Pneumonia, Viral; Protease Inhibitors; Pyrazines; SARS-CoV-2 | 2020 |
Sickle cell anemia and COVID-19: Use of voxelotor to avoid transfusion.
Topics: Adult; Anemia, Sickle Cell; Benzaldehydes; Combined Modality Therapy; COVID-19; COVID-19 Nucleic Acid Testing; Erythrocyte Transfusion; Female; Hematologic Agents; Hemoglobins; Humans; Hypoxia; Pyrazines; Pyrazoles | 2020 |
Characteristics and Management of Children with COVID-19 in Turkey
Topics: Adolescent; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Coronavirus Infections; COVID-19; Extracorporeal Membrane Oxygenation; Female; Humans; Hydroxychloroquine; Infant; Infant, Newborn; Intensive Care Units, Pediatric; Length of Stay; Male; Pandemics; Patient Acuity; Pneumonia, Viral; Pyrazines; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Turkey | 2020 |
Signal amplification by reversible exchange for COVID-19 antiviral drug candidates.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Discovery; Humans; Lopinavir; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Tolerability of favipiravir therapy in critically ill patients with COVID-19: A report of four cases.
Topics: Adult; Amides; COVID-19; Critical Illness; Female; Humans; Male; Middle Aged; Pyrazines | 2021 |
Comment on: Favipiravir, an antiviral for COVID-19?
Topics: Amides; Antiviral Agents; COVID-19; Humans; Pandemics; Pyrazines; SARS-CoV-2 | 2021 |
Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.
Topics: Amides; Antiviral Agents; COVID-19; Humans; Methylprednisolone; Pyrazines; SARS-CoV-2; Treatment Outcome | 2020 |
Monitoring of viral load by RT-PCR caused decision making to continue ECMO therapy for a patient with COVID-19.
Topics: Amides; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Decision Making; Extracorporeal Membrane Oxygenation; Hospitalization; Humans; Lung; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome; Viral Load | 2020 |
Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Humans; Kidney Failure, Chronic; Middle Aged; Pandemics; Positive-Pressure Respiration; Pyrazines; Renal Dialysis; SARS-CoV-2 | 2021 |
Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
Topics: Amides; Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Coronavirus Infections; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Models, Molecular; Mutagenesis; Pandemics; Pneumonia, Viral; Pyrazines; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Sequence Analysis; Vero Cells; Viral Nonstructural Proteins; Virus Replication | 2020 |
The effects of favipiravir on hematological parameters of covıd-19 patients.
Topics: Adult; Aged; Aged, 80 and over; Amides; Betacoronavirus; CD4 Lymphocyte Count; Coronavirus Infections; COVID-19; Female; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Pandemics; Platelet Count; Pneumonia, Viral; Pyrazines; Retrospective Studies; SARS-CoV-2 | 2020 |
Could ferritin level be an indicator of COVID-19 disease mortality?
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Female; Ferritins; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Prognosis; Pyrazines; SARS-CoV-2; Severity of Illness Index | 2021 |
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
Topics: Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Viral; Prospective Studies; Pyrazines; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
Topics: Administration, Oral; Aged; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pyrazines; RNA, Viral; SARS-CoV-2; Virus Shedding | 2020 |
Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
Topics: Adult; Amides; Antiviral Agents; Body Temperature; COVID-19; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Female; Fever; Humans; Male; Pyrazines; SARS-CoV-2; Treatment Outcome | 2020 |
Favipiravir for COVID-19 in a Patient on Hemodialysis.
Topics: Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Male; Pyrazines; Renal Dialysis | 2021 |
Characteristics and Management of Children With COVID-19 in a Tertiary Care Hospital in Turkey.
Topics: Adolescent; Amides; Antiviral Agents; Child; Child, Preschool; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Lung; Male; Pediatrics; Pyrazines; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Tertiary Care Centers; Treatment Outcome; Turkey | 2021 |
Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M
Topics: Antiviral Agents; Betacoronavirus; Binding Sites; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Drug Discovery; Humans; Hydrazones; Molecular Docking Simulation; Molecular Dynamics Simulation; Pandemics; Pneumonia, Viral; Protease Inhibitors; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Pyrazines; Pyrazoles; SARS-CoV-2; Thermodynamics; User-Computer Interface; Viral Nonstructural Proteins | 2020 |
Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast?
Topics: Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; SARS-CoV-2 | 2021 |
Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antimalarials; Antiviral Agents; Chlorocebus aethiops; Chloroquine; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Flow Cytometry; Heart Diseases; Humans; Hydroxychloroquine; Microscopy, Fluorescence; Myocytes, Cardiac; Pluripotent Stem Cells; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Vero Cells; Viral Plaque Assay | 2020 |
DFT calculations towards the geometry optimization, electronic structure, infrared spectroscopy and UV-vis analyses of Favipiravir adsorption on the first-row transition metals doped fullerenes; a new strategy for COVID-19 therapy.
Topics: Amides; COVID-19; COVID-19 Drug Treatment; Fullerenes; Humans; Molecular Structure; Pandemics; Pyrazines; SARS-CoV-2; Spectrophotometry, Infrared | 2021 |
Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Combinations; Female; Humans; Intensive Care Units; Length of Stay; Lopinavir; Male; Middle Aged; Mortality; Pyrazines; Ritonavir; SARS-CoV-2; Treatment Outcome; Turkey | 2021 |
Scientists criticize use of unproven COVID drugs in India.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; Drugs, Investigational; Humans; Hydroxychloroquine; India; Patient Safety; Placebos; Pyrazines; Reproducibility of Results; SARS-CoV-2; Time Factors; United States; Virus Shedding | 2020 |
A Favipiravir-induced Fever in a Patient with COVID-19.
Topics: Aged, 80 and over; Amides; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Fever; Humans; Male; Pandemics; Pneumonia, Viral; Pyrazines; SARS-CoV-2 | 2020 |
Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey
Topics: Adult; Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Female; Follow-Up Studies; Humans; Intensive Care Units; Male; Middle Aged; Pandemics; Pyrazines; Retrospective Studies; SARS-CoV-2; Time Factors; Treatment Outcome; Turkey | 2021 |
A case of COVID-19 pneumonia successfully treated with favipiravir (Avigan) in which serum SARS-CoV-2 RNA detected by LAMP method was clinically useful.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Nasopharynx; Nucleic Acid Amplification Techniques; Pneumonia, Viral; Pyrazines; Respiration, Artificial; RNA, Viral; SARS-CoV-2; Treatment Outcome; Viremia | 2021 |
Evidence-Based Guidelines Should Be Used To Inform COVID-19 Management.
Topics: Amides; COVID-19; Humans; Pyrazines; SARS-CoV-2 | 2021 |
Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.
Topics: Amides; COVID-19; Humans; Pyrazines; SARS-CoV-2 | 2021 |
Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.
Topics: Amides; COVID-19; Humans; Japan; Pyrazines; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2021 |
Gender differences in treatment of Coronavirus Disease-2019.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Amides; Antimalarials; Antiviral Agents; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; Combined Modality Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Diabetes Complications; Female; Humans; Hypertension; Immunity; Immunization, Passive; Immunoglobulins; Lopinavir; Male; Middle Aged; Mortality; Pandemics; Pyrazines; Ritonavir; SARS-CoV-2; Sex Characteristics | 2020 |
Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma.
Topics: Amides; Antiviral Agents; Blood Chemical Analysis; COVID-19; COVID-19 Drug Treatment; Humans; Limit of Detection; Pyrazines; SARS-CoV-2; Sensitivity and Specificity; Spectrometry, Fluorescence | 2021 |
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Amides; Benzamidines; Combined Modality Therapy; COVID-19; Dihydrotestosterone; Disease Progression; Female; Guanidines; Health Personnel; Heparin; Humans; Japan; Metyrapone; Neurosurgical Procedures; Pituitary ACTH Hypersecretion; Pregnenediones; Pyrazines; SARS-CoV-2; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
Subacute thyroiditis as a presenting manifestation of COVID-19: a report of an exceedingly rare clinical entity.
Topics: Amides; Antiviral Agents; Azithromycin; COVID-19; COVID-19 Drug Treatment; Diagnosis, Differential; Glucocorticoids; Humans; Male; Middle Aged; Prednisolone; Pyrazines; Radionuclide Imaging; SARS-CoV-2; Thyroid Function Tests; Thyroid Gland; Thyroiditis, Subacute; Treatment Outcome; Ultrasonography, Doppler, Color | 2020 |
Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid.
Topics: Adrenal Cortex Hormones; Aged; Amides; Antiviral Agents; COVID-19; Extracorporeal Membrane Oxygenation; Humans; Male; Methylprednisolone; Middle Aged; Pyrazines; Respiration, Artificial; Respiratory Insufficiency; SARS-CoV-2 | 2021 |
Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19.
Topics: Aged; Amides; Antiviral Agents; Chemical and Drug Induced Liver Injury; Cholestasis; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Extracorporeal Membrane Oxygenation; Humans; Lopinavir; Male; Pyrazines; Ritonavir; SARS-CoV-2 | 2021 |
Fluorescence of nails and hair on Wood's lamp examination in Covid pandemic; undefined effect of Favipiravir in humans.
Topics: Amides; COVID-19; Fluorescence; Humans; Nails; Pandemics; Pyrazines; SARS-CoV-2; Ultraviolet Rays | 2021 |
[Clinical progression of the first wave of novel coronavirus infection in Ostrava].
Topics: Adenosine Monophosphate; Aged; Alanine; Amides; COVID-19; Czech Republic; Female; Humans; Hydroxychloroquine; Length of Stay; Male; Pyrazines; Respiration, Artificial | 2020 |
Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; COVID-19; COVID-19 Drug Treatment; Cytokines; Drug Repositioning; Gene Expression Regulation; Humans; Piperidines; Pyrazines; SARS-CoV-2 | 2021 |
Fingernail lunula luminescence in COVID-19 patients: Is it a favipiravir-related reaction or a novel manifestation of coronavirus infection.
Topics: Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Luminescence; Nails; Pneumonia, Viral; Pyrazines; SARS-CoV-2; Turkey; Ultraviolet Rays | 2021 |
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum
Topics: Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Chloroquine; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Furans; Humans; Hydroxychloroquine; Isotopes; Lopinavir; Pandemics; Pyrazines; Pyrroles; Ritonavir; SARS-CoV-2; Tandem Mass Spectrometry; Triazines | 2021 |
Early clinical experience with imatinib in COVID-19: Searching for a dual effect.
Topics: Amides; COVID-19; Humans; Imatinib Mesylate; Pyrazines; SARS-CoV-2; Treatment Outcome | 2021 |
Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient.
Topics: Amides; Antiviral Agents; COVID-19; Fever; Humans; Male; Middle Aged; Pharmaceutical Preparations; Pyrazines; SARS-CoV-2 | 2021 |
Myositis due to COVID-19.
Topics: Adult; Amides; Antiviral Agents; C-Reactive Protein; COVID-19; COVID-19 Nucleic Acid Testing; Creatine Kinase; Fibrin Fibrinogen Degradation Products; Glucocorticoids; Humans; Hydroxychloroquine; Lung; Lymphopenia; Magnetic Resonance Imaging; Male; Methylprednisolone; Muscle, Skeletal; Myositis; Pyrazines; SARS-CoV-2; Tomography, X-Ray Computed | 2021 |
Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
Topics: Amides; COVID-19; Humans; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2021 |
Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
Topics: Amides; COVID-19; Humans; Pyrazines; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2021 |
Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19.
Topics: Amides; Blood Chemical Analysis; Chromatography, High Pressure Liquid; COVID-19; COVID-19 Drug Treatment; Hospitals; Humans; Pyrazines; Time Factors | 2021 |
Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra.
Topics: Adult; Aged; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokines; Drug Combinations; Female; Humans; Lopinavir; Male; Middle Aged; Pyrazines; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2021 |
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.
Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Cricetinae; Disease Models, Animal; Female; Genome, Viral; Lung; Mesocricetus; Pyrazines; SARS-CoV-2; Vero Cells; Viral Load | 2021 |
Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID-19 using favipiravir.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; COVID-19; Cross-Sectional Studies; Drug Combinations; Humans; Male; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Turkey | 2021 |
A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test.
Topics: Amides; COVID-19; COVID-19 Drug Treatment; Female; Fever; Humans; Lymphocyte Activation; Middle Aged; Pyrazines; Viral Load | 2021 |
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication.
Topics: A549 Cells; Animals; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; DNA Damage; Drug Evaluation, Preclinical; HEK293 Cells; HeLa Cells; Humans; Isoxazoles; MAP Kinase Signaling System; Middle East Respiratory Syndrome Coronavirus; Pyrazines; SARS-CoV-2; Vero Cells; Virus Replication | 2021 |
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report.
Topics: Adenosine Monophosphate; Adult; Alanine; Amides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Brentuximab Vedotin; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Dacarbazine; Disease Progression; Doxorubicin; Hodgkin Disease; Humans; Male; Pregnenediones; Pyrazines; Time Factors; Vinblastine | 2021 |
Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment.
Topics: Amides; China; COVID-19; Humans; Pyrazines; Real-Time Polymerase Chain Reaction; Recurrence; Reverse Transcription; SARS-CoV-2 | 2021 |
Japan's Drug Regulation During the COVID-19 Pandemic: Lessons From a Case Study of Favipiravir.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Clinical Trials, Phase III as Topic; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Double-Blind Method; Drug Approval; Humans; Japan; Pyrazines | 2022 |
Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.
Topics: Amides; Antiviral Agents; COVID-19; Critical Illness; Humans; Propensity Score; Pyrazines; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Saudi Arabia; Sensitivity and Specificity | 2021 |
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Darunavir; Disease Progression; Drug Combinations; Female; Hospitals; Hospitals, University; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pyrazines; Referral and Consultation; Retrospective Studies; Ritonavir; Thailand; Treatment Outcome; Young Adult | 2021 |
Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients.
Topics: Amides; Antiviral Agents; COVID-19; Humans; Male; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome | 2021 |
Evaluation of the frequency and intensity of favipiravir-associated yellow-green fluorescence in lunulae, hair, and face.
Topics: Amides; Antiviral Agents; COVID-19; Female; Fluorescence; Humans; Nails; Pyrazines; SARS-CoV-2 | 2022 |
Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19.
Topics: Aged; Aged, 80 and over; Amides; Antiviral Agents; Combined Modality Therapy; Comorbidity; COVID-19; COVID-19 Serotherapy; Critical Care; Female; Fibrin Fibrinogen Degradation Products; Follow-Up Studies; Hospital Mortality; Humans; Immunization, Passive; Leukocyte Count; Male; Middle Aged; Pandemics; Pyrazines; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Time Factors; Turkey | 2021 |
Yellow-white fluorescence on the nails: A novel finding of Favipiravir used for the treatment of COVID-19.
Topics: Amides; COVID-19; Fluorescence; Humans; Nails; Pyrazines; SARS-CoV-2 | 2021 |
Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs.
Topics: Amides; COVID-19; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protease Inhibitors; Pyrazines; SARS-CoV-2 | 2022 |
A case report of super responder of critical COVID-19 pneumonia.
Topics: Aged; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Critical Illness; Drug Therapy, Combination; Glucocorticoids; Humans; Lung; Male; Methylprednisolone; Pneumonia, Viral; Pyrazines; Receptors, Interleukin-6; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2021 |
Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study.
Topics: Aged; Amides; Antiviral Agents; Case-Control Studies; COVID-19; COVID-19 Drug Treatment; Drug Administration Schedule; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome | 2021 |
Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum.
Topics: Amides; Antiviral Agents; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Drug Stability; Humans; Limit of Detection; Pyrazines; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2021 |
Management of COVID-19 pneumonia in a child with NEMO deficiency.
Topics: Amides; Antiviral Agents; Azithromycin; Child; COVID-19; COVID-19 Serotherapy; Ectodermal Dysplasia; Genetic Diseases, X-Linked; Humans; Hydroxychloroquine; I-kappa B Kinase; Immunization, Passive; Male; Primary Immunodeficiency Diseases; Pyrazines; SARS-CoV-2 | 2021 |
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.
Topics: Amides; Animals; Antiviral Agents; COVID-19; Dogs; Humans; Polyphosphates; Pyrazines; SARS-CoV-2 | 2021 |
Bilateral foot ulcers in a COVID-19 patient under favipiravir treatment.
Topics: Amides; COVID-19; Diabetic Foot; Humans; Pyrazines; SARS-CoV-2 | 2021 |
Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antimalarials; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Male; Middle Aged; Outpatients; Pyrazines; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Turkey; Young Adult | 2021 |
Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
Topics: Amides; COVID-19; Humans; Pyrazines; SARS-CoV-2 | 2022 |
Favipiravir Induced Nephrotoxicity in Two Patients of COVID-19.
Topics: Amides; Antiviral Agents; COVID-19; Humans; Pyrazines; SARS-CoV-2 | 2021 |
A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma.
Topics: Amides; Antiviral Agents; Bone Neoplasms; Chemical and Drug Induced Liver Injury; COVID-19; Humans; Methotrexate; Osteosarcoma; Pharmaceutical Preparations; Pyrazines; RNA, Viral; SARS-CoV-2 | 2022 |
Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report.
Topics: Adult; Amides; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Eye; Fluorescence; Humans; Male; Pyrazines; SARS-CoV-2 | 2021 |
Population pharmacokinetics of favipiravir in patients with COVID-19.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Theoretical; Pyrazines; Retrospective Studies; Tandem Mass Spectrometry; Treatment Outcome | 2021 |
A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection.
Topics: Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Imidazoles; Pyrazines; Salmeterol Xinafoate; SARS-CoV-2; Vero Cells; Virus Internalization | 2021 |
Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients
Topics: Adenosine Monophosphate; Adolescent; Adult; Aged; Aged, 80 and over; Alanine; Amides; Antiviral Agents; Clinical Protocols; COVID-19; COVID-19 Nucleic Acid Testing; Female; Humans; Hydroxychloroquine; Length of Stay; Male; Middle Aged; Oseltamivir; Pandemics; Pyrazines; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Treatment Outcome; Young Adult | 2021 |
Alectinib, COVID-19 and favipiravir.
Topics: Amides; Carbazoles; COVID-19; Humans; Piperidines; Pyrazines; SARS-CoV-2 | 2021 |